How Cardinal Health, Inc. Makes Money

Cardinal Health, Inc. generates revenue through a healthcare supply chain intermediary model that operates on razor-thin margins but enormous volume, supplemented by higher-margin manufactured products and specialized services. The core mechanism is pharmaceutical distribution: the company purchases branded, generic, and specialty pharmaceutical products from manufacturers at negotiated prices, holds inventory in national distribution centers, and sells to retail pharmacy chains, independent pharmacies, hospital networks, mail-order facilities, long-term care facilities, and other healthcare providers. Revenue is recognized at the point of delivery, and gross profit is the difference between the selling price and the cost of products sold, plus fees for distribution services, data reporting, and value-added programs. For fiscal 2025, the Pharmaceutical and Specialty Solutions segment generated $204.6 billion in revenue (92% of consolidated sales) and $2.26 billion in segment profit, yielding a segment profit margin of 1.10%. This margin is typical for pharmaceutical wholesale and reflects the commodity-like nature of distribution: the product (pharmaceuticals) is largely undifferentiated, and competition is based on price, service levels, and geographic coverage rather than proprietary technology. The segment profit growth of 12% in fiscal 2025, despite a 3% revenue decline, demonstrates the company's ability to improve profitability through product mix shifts—specifically, growth in higher-margin branded and specialty pharmaceuticals and BioPharma Solutions services that offset the OptumRx contract loss. The gross margin rate for the Pharmaceutical segment improved 36 basis points year-over-year to 3.57% in the first half of fiscal 2025, driven by favorable product mix changes and the expiration of the low-margin OptumRx contracts. The Global Medical Products and Distribution segment operates a fundamentally different business model. This segment manufactures, sources, and distributes Cardinal Health-branded medical, surgical, and laboratory products including exam and surgical gloves, needles and syringes, compression and wound care products, surgical drapes and gowns, fluid management systems, and urology products. It also distributes national brand medical products and assembles sterile and non-sterile procedure kits. The segment generated $12.6 billion in fiscal 2025 revenue and $135 million in segment profit (1.07% margin). The manufacturing component provides higher margins than pure distribution, but the segment has struggled with profitability, recording a $585 million goodwill impairment in fiscal 2023 related to the Wavemark business and continuing to face competitive pressure from lower-cost manufacturers. The 'Other' businesses represent Cardinal Health's highest-margin operations and its strategic growth vector. Nuclear and Precision Health Solutions operates the nation's largest network of nuclear pharmacies, manufacturing, preparing, and delivering radiopharmaceuticals for use in nuclear imaging and therapeutic procedures. This business requires specialized regulatory compliance, short half-life logistics, and clinical expertise that create significant barriers to entry. at-Home Solutions distributes direct-to-patient medical supplies including diabetes products, ostomy supplies, and wound care materials. OptiFreight Logistics provides freight optimization and supply chain services. Collectively, these businesses generated $5.4 billion in fiscal 2025 revenue and $516 million in segment profit (9.59% margin)—nearly nine times the margin of the core pharmaceutical distribution business. The revenue model across all segments is characterized by several key features. First, customer concentration is extreme: OptumRx represented 17% of fiscal 2024 revenue before contract expiration, and CVS Health (through both direct distribution and the Red Oak Sourcing joint venture) remains a critical customer. The company discloses that it has 'significant customer concentration' and that the loss of any major customer would materially affect results. Second, generic pharmaceutical pricing is volatile and generally deflationary. Generic drug prices typically decline over time as additional manufacturers enter the market, and the frequency of generic price appreciation (which boosts distributor margins) is unpredictable. The Red Oak Sourcing joint venture with CVS Health, established in 2014 as a 50/50 entity, is designed to mitigate this volatility by combining purchasing power to negotiate better terms with generic manufacturers. Red Oak is one of the largest generic drug buyers in the United States, responsible for securing generic pharmaceuticals for over 9,000 CVS retail locations, Caremark mail-order facilities, and Cardinal Health's distribution network. Third, branded pharmaceutical distribution generates fees rather than product margin. Under distribution service agreements with branded manufacturers, Cardinal Health receives fees for providing distribution, inventory management, data reporting, and other services. These fees are generally stable and less volatile than generic pricing, but they are subject to renegotiation and competitive pressure. Fourth, specialty pharmaceuticals—including oncology, rheumatology, urology, and plasma products—represent a growth area with higher margins than traditional distribution. The company has invested heavily in specialty pharmacy capabilities, patient support programs, and consulting services for manufacturers. The acquisitions of ION (oncology), GI Alliance (gastroenterology), ADSG (diabetes), and Solaris Health (urology) are designed to deepen these specialty capabilities and create integrated care networks that capture more value from the pharmaceutical supply chain. The cost structure reflects the scale-intensive nature of the business. Cost of products sold was $214.4 billion in fiscal 2025 (96.3% of revenue), leaving a gross margin of $8.17 billion (3.67%). Distribution, selling, general, and administrative expenses were $5.38 billion, amortization and acquisition-related costs were $464 million, and restructuring costs were $88 million. The operating leverage is significant: a small improvement in gross margin rate (36 basis points in the first half of fiscal 2025) translates to substantial profit growth given the revenue base. The company generated $2.5 billion in adjusted free cash flow in fiscal 2025 and has guided to approximately $2 billion in average annual free cash flow from fiscal 2024 to 2026. Capital allocation priorities include share repurchases ($500 million guided for fiscal 2025), debt reduction, and acquisitions in higher-margin healthcare services.

Cardinal Health's growth strategy under CEO Jason Hollar rests on four specific, named initiatives with measurable targets: (1) growing Pharmaceutical and Specialty Solutions segment profit at a 4-6% compound annual growth rate through product mix optimization and specialty pharmaceutical expansion; (2) building a diversified specialty care platform through acquisitions in oncology, gastroenterology, diabetes, and urology; (3) expanding the highest-margin 'Other' businesses including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics; and (4) maintaining adjusted free cash flow of approximately $2 billion annually to fund acquisitions, share repurchases, and debt reduction. The Pharmaceutical and Specialty Solutions segment profit growth target of 4-6% CAGR is the core financial objective. This growth is expected to come from several sources: increased contribution from branded pharmaceutical and specialty pharmaceutical products, which carry higher margins than generic distribution; growth from BioPharma Solutions, including Specialty Networks that provide consulting, patient support, and data services to manufacturers and providers; and the accretive impact of recent acquisitions. The company has demonstrated this playbook in fiscal 2025, when segment profit grew 12% despite a 3% revenue decline, as the expiration of low-margin OptumRx contracts improved overall segment profitability. The specialty care platform strategy is the most transformative initiative. Cardinal Health has acquired or invested in four major specialty care organizations: Integrated Oncology Network (ION), a network of community oncology practices; a 71% stake in GI Alliance, the largest gastroenterology practice management organization in the United States; Advanced Diabetes Supply Group (ADSG) for approximately $1.1 billion, serving approximately 500,000 patients annually; and Solaris Health, the country's leading urology MSO. These acquisitions are designed to create integrated care networks that combine drug distribution, practice management, patient support, and care coordination. The strategic logic is that by positioning deeper in the care delivery chain—at the physician practice level—Cardinal Health can capture more value from the pharmaceutical supply chain and generate higher-margin, recurring revenues that are less susceptible to the pricing pressure affecting pure distribution. The Nuclear and Precision Health Solutions growth strategy targets the expanding diagnostic and therapeutic radiopharmaceutical market. The company's network of nuclear pharmacies provides time-critical radiopharmaceutical doses to hospitals and imaging centers, a service with significant barriers to entry and stable demand. The expansion of therapeutic radiopharmaceuticals, particularly in oncology (e.g., Lutathera for neuroendocrine tumors, Pluvicto for prostate cancer), creates new growth opportunities. The at-Home Solutions strategy addresses the shift toward home-based care. The ADSG acquisition provides diabetes supplies to approximately 500,000 patients annually, creating a recurring revenue stream with direct patient relationships. The company is positioned to benefit from the trend of more chronic disease management occurring in patients' homes rather than in clinical settings. OptiFreight Logistics provides supply chain optimization services that are increasingly valuable as healthcare providers seek to reduce logistics costs. The capital allocation strategy is equally specific. The company has guided to approximately $2 billion in average annual adjusted free cash flow from fiscal 2024 to 2026. This cash flow is allocated to: share repurchases ($500 million guided for fiscal 2025, with continued buybacks expected); debt reduction (to maintain investment-grade credit ratings); and acquisitions (with a focus on specialty care platforms and higher-margin services). The company has stated that it intends to finance acquisitions with a combination of cash on hand and debt financing. The long-term targets, reaffirmed in April 2024 despite the OptumRx loss, include: Pharmaceutical and Specialty Solutions segment profit CAGR of 4-6%; consolidated non-GAAP EPS CAGR of 12-14% for fiscal years 2024 to 2026 (relative to a fiscal 2023 baseline); and adjusted free cash flow of approximately $2 billion on average annually. These targets imply that management believes the company can achieve sustained earnings growth even in a challenging revenue environment.